Related Experiment Video

Updated: Jul 1, 2026

Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays
11:17

Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays

Published on: January 7, 2016

Clinical inquiries: can recombinant growth hormone effectively treat idiopathic short stature?

Tim Von Fange1, Todd McDiarmid, Leslie Mackler

  • 1Moses Cone Family Medicine Residency Program, Greensboro, NC, USA.

The Journal of Family Practice
|September 13, 2008
PubMed

Insights

Recombinant human growth hormone (rGH) injections can increase final height by 3.7 to 7.5 cm in children with idiopathic short stature. This treatment, administered over 4-6 years, is recommended for children aged 8-16 with a height SDS of -2.0 or less.

Area of Science:

  • Pediatrics
  • Endocrinology
  • Growth disorders

Background:

  • Idiopathic short stature (ISS) affects children who are otherwise healthy.
  • Defining ISS involves a height standard deviation score (SDS) of -2.0 or less, representing the bottom 2.5% of height percentiles.
  • Adequate response to growth hormone stimulation testing is a key diagnostic criterion.

Purpose of the Study:

  • To evaluate the efficacy of recombinant human growth hormone (rGH) in increasing final height for children with ISS.
  • To determine the optimal treatment duration and dosage for rGH therapy in this population.

Main Methods:

  • The study analyzed data from 2 small, low-quality randomized controlled trials (RCTs).
  • Treatment involved rGH injections administered at least 3 times per week.
  • The treatment duration ranged from 4 to 6 years.

Main Results:

  • rGH treatment resulted in an increase in final height ranging from 3.7 to 7.5 cm.
  • The observed height increase was noted in children aged 8 to 16 years with ISS.
  • The positive outcomes were observed in children meeting specific height and hormonal criteria.

Conclusions:

  • rGH therapy is an effective treatment for increasing final height in children diagnosed with idiopathic short stature.
  • Long-term treatment (4-6 years) with rGH injections shows significant benefits for eligible children.
  • Further high-quality research is warranted to confirm these findings and refine treatment protocols.

More Related Videos

Treatment of Ligament Constructs with Exercise-conditioned Serum: A Translational Tissue Engineering Model08:03

Treatment of Ligament Constructs with Exercise-conditioned Serum: A Translational Tissue Engineering Model

Published on: June 11, 2017

Related Concept Videos

Nature and Nurture01:10

Nature and Nurture

Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience, such as differences...
Hormones and Bone Tissue01:17

Hormones and Bone Tissue

The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Recombinant DNA01:09

Recombinant DNA

Overview
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...